Nystatin is a polyene ionophore antifungal used to treat cutaneous, mucocutaneous, and gastrointestinal mycotic infections, particularly those caused by Candida species.

Brand Names
Flagystatin, Mycostatin, Nyaderm, Nyamyc, Nystop, Viaderm Kc
Generic Name
DrugBank Accession Number

Nystatin is a polyene antifungal drug that has broad-spectrum fungicidal and fungistatic activity against a number of yeasts and fungi, most notably Candida species.8 It is one of the most effective antifungal agents synthesized by bacteria, in this case a strain of Streptomyces noursei,13 and is closely related to amphotericin B, differing only slightly in structure.2 Nystatin has a greater antifungal activity than amphotericin B - parenterally administered nystatin, however, is associated with significant toxicity and is not available in a formulation appropriate for systemic use.2 As it undergoes very little absorption following oral or topical administration, nystatin's efficacy is limited to the treatment/prevention of cutaneous, mucocutaneous, and gastrointestinal fungal infections.8,9

Small Molecule
Approved, Vet approved
Average: 926.107
Monoisotopic: 925.503499959
Chemical Formula
  • Nistatina
  • NYS
  • Nystatin
  • Nystatine
  • Nystatinum



Nystatin is available in oral formulations for the treatment and/or prevention of oral candidiasis (a.k.a. thrush), intestinal candidiasis, and anal candidiasis.8,9 It is indicated topically for the treatment of vulvovaginal candidiasis and other cutaneous candida infections.9 A combination product containing nystatin alongside neomycin, gramicidin D, and triamcinolone (Viaderm K.C.®) is indicated in the treatment of corticosteroid-responsive dermatoses caused by bacterial or candidal infections and for pruritus ani/vulvae.10 It is also available in combination with metronidazole for the treatment of mixed infections due to Trichomonas vaginalis and Candida albicans.13

Nystatin is also sometimes used off-label for the prevention of invasive candidiasis in low birth weight neonates,4 though it is generally reserved as a second-line option after fluconazole.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Prophylaxis ofAnal candidiasis••• •••••••••
Treatment ofAnal candidiasis••• •••••••••
Treatment ofCandidiasis, cutaneous•••••••••••••••••• ••••••••
Prophylaxis ofCandidiasis, invasive••• •••••••••••••••• ••••• ••••••
Prophylaxis ofIntestinal candidiasis••• •••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more

Nystatin is an antifungal that is both fungistatic and fungicidal in vitro against a wide variety of yeasts and yeast-like fungi. It exerts its antifungal effects via disruption of the fungal cell membrane. Resistance to nystatin is minimal in Candida albicans, but tends to develop in other species of Candida.8 Nystatin carries no significant activity against bacteria, protozoa, or viruses. It carries significant systemic toxicity and is currently unavailable in a formula appropriate for systemic use - its efficacy is currently restricted, therefore, to topical, oral, and gastrointestinal infections.2

Mechanism of action

Nystatin is a channel-forming ionophore, meaning it exerts its therapeutic effect via formation of a membrane-spanning pore in the fungal plasma membrane.5 The formation of this pore results in a change in membrane permeability that allows for leakage of intracellular contents and the subsequent disruption of electrochemical gradients necessary for proper cell function.8,2 Selectivity for fungal cells over mammalian cells is due to nystatin’s greater binding affinity for ergosterol, a key sterol found in fungal cell walls, as opposed to its mammalian counterpart, cholesterol.6

Candida albicans

Systemic absorption of nystatin is minimal following oral administration,8 and no detectable plasma concentrations are attained following topical or vaginal administration.12

Volume of distribution

Nystatin is not absorbed into the systemic circulation8 and thus does not undergo distribution.

Protein binding

Nystatin is not absorbed into the systemic circulation8 and is therefore not subject to plasma protein binding.


Because nystatin undergoes little-to-no systemic absorption it is not metabolized to any appreciable extent.8

Route of elimination

The majority of orally administered nystatin is eliminated unchanged in the feces.8


Not Available


Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample

The oral LD50 in rats is 10 g/kg.11 There have been no reports of serious toxic effects following overdosage of nystatin - doses in excess of five million units daily have resulted in nausea and gastrointestinal upset with no other associated effects.8

Not Available
Pharmacogenomic Effects/ADRs
Not Available


Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
AmbrisentanThe excretion of Ambrisentan can be decreased when combined with Nystatin.
AsunaprevirThe excretion of Asunaprevir can be decreased when combined with Nystatin.
AtogepantThe serum concentration of Atogepant can be increased when it is combined with Nystatin.
AtorvastatinThe excretion of Atorvastatin can be decreased when combined with Nystatin.
AxitinibThe excretion of Axitinib can be decreased when combined with Nystatin.
Food Interactions
No interactions found.


Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Nystatin dihydrateNot AvailableNot AvailableVXWFKTGGEJLHPP-WFCLXGQZSA-N
Product Images
International/Other Brands
Adiclair (Ardeypharm) / Afunginal (Euro Generics) / Biofanal (Pfleger) / Candacide (Be-Tabs Pharmaceuticals) / Candermil (LKM) / Candex (Square) / Candidias (Fabra) / Candistat (Ambalal Sarabhai Enterprises) / Candistin (Pharos) / Canstat (Aspen Pharmacare) / Cazetin (Ifars) / Diaper NZ (Cheminter) / Dipni (Omega) / Enystin (Kalbe) / Fukangning (Deyer) / Fungatin (Ferron) / Fungicidin Leciva (Zentiva) / Fungistin (Beximco) / Fungostatin (Nobel) / Funistatin (Nobel) / Gynostatin (Iqfarma) / Kandistatin (Metiska) / Kenalon (Ta Fong) / Lederlind (Riemser) / Ledernyst (Riemser) / Lystin (Biolab) / Nilstat (Glenmark) / Nyaderm (Taro) / Nystan (Bristol Myers Squibb)
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
MestatinCream25000 unit / gVaginalMedic Laboratory LtÉe1980-12-311996-09-09Canada flag
Mycostatin Oral Suspension 100000iuLiquid100000 unit / mLOralSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.1972-12-312003-07-28Canada flag
Mycostatin Oral Tab 500000iuTablet500000 unitOralSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.1955-12-312002-07-30Canada flag
Mycostatin Vaginal Crm 25000unitCream25000 unit / gVaginalSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.1973-12-312005-08-01Canada flag
Nadostine Sus 100000iu/mlSuspension100000 unit / mLOralLab Nadeau LtÉe, Division Of Technilab Inc.1974-12-312004-08-03Canada flag
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Dom-nystatin SuspensionSuspension100000 unit / mLOralDominion Pharmacal1998-08-05Not applicableCanada flag
Ftp-nystatinSolution / drops100000 unit / mLOralFtp Pharmacal Inc.1998-10-092004-08-03Canada flag
Jamp-nystatin Oral Suspension USPSuspension100000 unit / mLOralJamp Pharma Corporation2015-01-09Not applicableCanada flag
KlayestaPowder100000 U/1gTopicalEpic Pharma, LLC2023-04-14Not applicableUS flag
MycostatinCream100000 [USP'U]/1gTopicalE.R. Squibb & Sons, L.L.C.2007-01-012007-06-30US flag
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Candistatin Topical Powder - 100000 Unit/gPowder100000 unit / gTopicalBristol Myers Squibb1996-12-312008-04-25Canada flag
Mycostatin Crm 100000unit/gmCream100000 unit / gTopicalSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.1970-12-312006-09-06Canada flag
Mycostatin Ont 100000iu/gmOintment100000 unit / gTopicalSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.1955-12-312002-07-30Canada flag
Mycostatin Topical Pwr 100,000units/gmPowder100000 unit / gTopicalConvatec, Division Of Bristol Myers Squibb Canada Co.1994-12-312008-11-12Canada flag
Nadostine Crm 100000iu/gmCream100000 unit / gTopicalLab Nadeau LtÉe, Division Of Technilab Inc.1974-12-312004-08-03Canada flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
APOLIND WUNDBAL M NYSTATINNystatin (70000 IU/g) + Zinc oxide (492 mg/g)SuspensionOral2006-07-01Not applicableGermany flag
APOLIND WUNDBAL M NYSTATINNystatin (70000 IU/g) + Zinc oxide (492 mg/g)SuspensionOral2006-07-01Not applicableGermany flag
BABYLIND MEDICADA® CREMA TÓPICA.Nystatin (100 %) + Zinc oxide (20 g)CreamTopicalLABORATORIOS DEMAC LTDA.2020-12-16Not applicableColombia flag
BABYSKIN® N CREMANystatin (2.2727 g) + Zinc oxide (40 g)CreamTopicalALTEA FARMACEUTICA S.A.2009-06-24Not applicableColombia flag
CREMA N°. 4® MEDICADANystatin (10000000 millions) + Zinc oxide (20 g)CreamTopicalTECNOFAR TQ S.A.S2006-11-10Not applicableColombia flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
FIRST BXN MouthwashNystatin (6.75 mg/1mL) + Diphenhydramine hydrochloride (0.84 mg/1mL) + Lidocaine hydrochloride (6.75 mg/1mL)KitOralCutisPharma, Inc2009-09-08Not applicableUS flag
FIRST Dukes Mouthwash CompoundingNystatin (0.6 g/0.6g) + Diphenhydramine hydrochloride (0.525 g/0.525g) + Hydrocortisone (0.06 g/0.06g)KitOralCutisPharma, Inc.2010-12-15Not applicableUS flag
FIRST Marys Mouthwash CompoundingNystatin (1.2 g/1.2g) + Diphenhydramine hydrochloride (0.45 g/0.45g) + Hydrocortisone (0.06 g/0.06g) + Tetracycline hydrochloride (1.5 g/1.5g)KitOralCutisPharma, Inc.2010-12-15Not applicableUS flag
MIKOSTATIN 100.000 I.U./ML ORAL SÜSPANSİYON 48 MLNystatin (100000 i.u./ml)OralDeva Holding A.S.2013-01-29Not applicableTurkey flag


ATC Codes
D01AA01 — NystatinG01AA01 — NystatinA07AA02 — NystatinG01AA51 — Nystatin, combinations
Drug Categories
Not classified
Affected organisms
  • Fungi

Chemical Identifiers

CAS number
InChI Key
(1S,3R,4R,7R,9R,11R,15S,16R,17R,18S,19E,21E,25E,27E,29E,31E,33R,35S,36R,37S)-33-{[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy}-1,3,4,7,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,25,27,29,31-hexaene-36-carboxylic acid


General References
  1. Akaike N, Harata N: Nystatin perforated patch recording and its applications to analyses of intracellular mechanisms. Jpn J Physiol. 1994;44(5):433-73. [Article]
  2. Dos Santos AG, Marques JT, Carreira AC, Castro IR, Viana AS, Mingeot-Leclercq MP, de Almeida RFM, Silva LC: The molecular mechanism of Nystatin action is dependent on the membrane biophysical properties and lipid composition. Phys Chem Chem Phys. 2017 Nov 15;19(44):30078-30088. doi: 10.1039/c7cp05353c. [Article]
  3. Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, Artursson P: Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem. 2012 May 24;55(10):4740-63. doi: 10.1021/jm300212s. Epub 2012 May 15. [Article]
  4. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE, Sobel JD: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016 Feb 15;62(4):e1-50. doi: 10.1093/cid/civ933. Epub 2015 Dec 16. [Article]
  5. Yamasaki M, Tamura N, Nakamura K, Sasaki N, Murakami M, Rajapakshage W, Kumara B, Tamura Y, Lim SY, Ohta H, Takiguchi M: Effects and mechanisms of action of polyene macrolide antibiotic nystatin on Babesia gibsoni in vitro. J Parasitol. 2011 Dec;97(6):1190-2. doi: 10.1645/GE-2799.1. Epub 2011 Jul 14. [Article]
  6. Silva L, Coutinho A, Fedorov A, Prieto M: Competitive binding of cholesterol and ergosterol to the polyene antibiotic nystatin. A fluorescence study. Biophys J. 2006 May 15;90(10):3625-31. Epub 2006 Feb 24. [Article]
  7. Liu W, Guan X, Yu Z, Chen K, Benet L, Zhai S: A Drug-drug Interaction Between Cyclosporine and Nystatin. Clin Ther. 2018 Apr;40(4):660-662. doi: 10.1016/j.clinthera.2018.02.008. Epub 2018 Mar 16. [Article]
  8. FDA Approved Drug Products: Nystatin oral suspension [Link]
  9. DPD Approved Drugs: Nystatin [Link]
  10. DPD Approved Drugs: Viaderm K.C.® [Link]
  11. ThermoFisher Scientific: Nystatin MSDS [Link]
  12. MedSafe NZ: Nystatin [Link]
  13. DPD Approved Drugs: Flagystatin® vaginal ovules [Link]
Human Metabolome Database
KEGG Compound
PubChem Compound
PubChem Substance
Therapeutic Targets Database
RxList Drug Page
Drugs.com Drug Page
PDRhealth Drug Page
FDA label
Download (776 KB)
Download (72.5 KB)

Clinical Trials

Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package
PhaseStatusPurposeConditionsCountStart DateWhy Stopped100+ additional columns
4CompletedHealth Services ResearchRenal Failure, Chronic Renal Failure1somestatusstop reasonjust information to hide
4CompletedPreventionCandidiasis / Critically Ill Patients / Fungal Prophylaxis / Surgery1somestatusstop reasonjust information to hide
4CompletedPreventionSystemic Fungal Infections1somestatusstop reasonjust information to hide
4CompletedPreventionVery Low Birthweight Infants1somestatusstop reasonjust information to hide
4CompletedTreatmentPhotochemotherapy Reaction1somestatusstop reasonjust information to hide


  • Bayer pharmaceuticals corp
  • Bristol myers squibb co
  • Alpharma us pharmaceuticals division
  • Lederle laboratories div american cyanamid co
  • Actavis mid atlantic llc
  • Altana inc
  • Perrigo new york inc
  • Taro pharmaceuticals usa inc
  • Teva pharmaceuticals usa inc
  • Vintage pharmaceuticals llc
  • Westwood squibb pharmaceuticals inc
  • Bristol myers squibb
  • Barlan pharmacal co inc
  • Dava pharmaceuticals inc
  • Paddock laboratories inc
  • Coastal pharmaceuticals inc
  • Kv pharmaceutical co
  • Par pharmaceutical inc
  • Upsher smith laboratories inc
  • X gen pharmaceuticals inc
  • Warner chilcott co llc
  • Apothecon inc div bristol myers squibb
  • Glenmark generics inc usa
  • Bausch and lomb pharmaceuticals inc
  • E fougera div altana inc
  • Morton grove pharmaceuticals inc
  • Pharmaderm div altana inc
  • Pharmafair inc
  • Roxane laboratories inc
  • Vintage pharmaceuticals inc
  • Vistapharm inc
  • Wockhardt eu operations (swiss) ag
  • Savage laboratories inc div altana inc
  • Mutual pharmaceutical co inc
  • Quantum pharmics ltd
  • Sandoz inc
  • Usl pharma inc
  • Watson laboratories inc
  • Holland rantos co inc
  • Odyssey pharmaceuticals inc
  • Actavis Group
  • Advanced Pharmaceutical Services Inc.
  • Aidarex Pharmacuticals LLC
  • Apothecon
  • A-S Medication Solutions LLC
  • Atlantic Biologicals Corporation
  • Bausch & Lomb Inc.
  • Bryant Ranch Prepack
  • Cardinal Health
  • Contract Pharm
  • Cutis Pharma Inc.
  • Dept Health Central Pharmacy
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Duramed
  • E. Fougera and Co.
  • E.R. Squibb and Sons LLC
  • Gallipot
  • Glenmark Generics Ltd.
  • Major Pharmaceuticals
  • Medisca Inc.
  • Metrics Inc.
  • Midlothian Labs
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mutual Pharmaceutical Co.
  • Novopharm Ltd.
  • Nycomed Inc.
  • Odyssey Pharmaceuticals Inc.
  • Paddock Labs
  • Palmetto Pharmaceuticals Inc.
  • Par Pharmaceuticals
  • PD-Rx Pharmaceuticals Inc.
  • Perrigo Co.
  • Pharmaceutical Association
  • Pharmaceutics International Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Pliva Inc.
  • Precision Dose Inc.
  • Preferred Pharmaceuticals Inc.
  • Qualitest
  • Rebel Distributors Corp.
  • Sandoz
  • Savage Labs
  • Stat Scripts LLC
  • Taro Pharmaceuticals USA
  • Teva Pharmaceutical Industries Ltd.
  • USL Pharma Inc.
  • Vintage Pharmaceuticals Inc.
  • Vistapharm Inc.
  • Wockhardt Ltd.
  • Xactdose Inc.
  • X-Gen Pharmaceuticals
Dosage Forms
CreamTopical100000 IU/g
OintmentTopical100000 IU/g
SuspensionOral100000 IU/g
Tablet, film coatedOral500000 IU
GelTopical100000 IU/g
TabletVaginal100000 UI
Tablet, sugar coatedOral500000 IU/1
KitTopical25 G
SuspensionOral000 UI
CreamTopical100000 USP
OintmentTopical100000 USP
SuspensionOral100000 USP
GelTopical250000 USP
PasteTopical100000 USP
CreamTopical100000 U/g
Solution / drops; suspension / drops100 IU/ML
SuspensionOral24 doz
SuspensionOral100000 IU/ML
InsertVaginal500.00 mg
Solution / dropsOral100000 unit / mL
Powder, for suspensionOral100000 iu/ml
Tablet, coatedOral500000 IU
SuspensionOral1710.623 mg
SuspensionOral100 IU/L
PasteTopical100000 IU/g
InsertVaginal500 mg
SuspensionOral30 ml
CreamVaginal100000 IU/g
Pill500000 U
PowderTopical100000 [USP'U]/1g
SuspensionOral100000 UI/ML
Tablet, film coatedOral
LiquidOral100000 unit / mL
PowderTopical100000 unit / g
SuspensionOral100000 unit / mL
TabletVaginal100000 unit
TabletOral500000 unit / tab
CreamVaginal100000 unit / g
TabletVaginal100000 unit / tab
SuspensionOral0 IU
Tablet, coatedOral
InsertVaginal100 IU
TabletVaginal100 IU
SuspensionOral10000000 IU
SuspensionOral2000 mg
SuspensionOral1.94 g
CreamTopical10 millions
InsertVaginal100000 IU
Tablet, coatedOral50000000000 IU
TabletVaginal000 UI
SuspensionOral100 IU/ML
CreamVaginal25000 unit / g
SuppositoryVaginal100000 IU
KitTopical100000 U/1g
SuspensionOral100000 IU
CreamOral; Topical100000 [USP'U]/1g
CreamTopical100000 1/1g
CreamTopical100000 [USP'U]/1g
CreamTopical100000 U/1g
CreamTopical100000 mg/1g
InsertVaginal100000 [USP'U]/1
OintmentTopical100000 U/1g
OintmentTopical100000 [USP'U]/1g
OintmentTopical100000 1/1g
Powder, for suspensionOral5000
Solution / drops; suspension / drops
SuspensionOral100000 U/1mL
SuspensionOral100000 [USP'U]/15mL
SuspensionOral100000 [iU]/1mL
SuspensionOral100000 [USP'U]/1mL
SuspensionOral500000 [USP'U]/5mL
Tablet, coatedOral500000 [USP'U]/1
Tablet, film coatedOral500000 [USP'U]/1
Tablet, sugar coatedOral
SolutionOral100000 [USP'U]/1mL
Tablet, sugar coatedOral500000 IU
TabletOral500000 IU
PowderTopical100000 U/1g
TabletVaginal100000 units
OintmentAuricular (otic)
KitTopical100000 [USP'U]/1g
SuspensionOral500000 u/5ml
CapsuleVaginal35000 iu
CreamTopical100000 unit / g
OintmentTopical100000 unit / g
TabletOral500000 unit
CreamTopical2.059 g
SuspensionOral100000 U/mL
CapsuleOral500000 IU
SuspensionOral100000 UNITS/1ML
Tablet, sugar coatedOral500000 UNITS
TabletVaginal100000 iu
Unit descriptionCostUnit
Nystatin 10 billion unit powder3014.1USD each
Nystatin 5 billion unit powder2096.1USD each
Nystatin 2 billion unit powder1116.9USD each
Nystatin 1 billion unit powder452.08USD each
Nystat-rx 5 billion unit powder447.0USD each
Nystatin 500 million unit powder130.75USD each
Pedi-Dri 100000 unit/gm Powder 56.7 gm Bottle105.87USD bottle
Nystatin 150mu Bottle94.5USD bottle
Nystatin 150 million unit powder42.25USD each
Nystatin 150000000 unit powder42.0USD each
Nystatin Nystatin Powder 50 Million unit Bottle39.99USD bottle
Mycostatin 100000 unit/gm Powder 15 gm Bottle36.99USD bottle
Nystop 100000 unit/gm Powder 15 gm Bottle29.99USD bottle
Nystatin 50 million unit powder19.75USD each
Nystatin 100000 unit/gm Ointment 15 gm Tube12.99USD tube
Nystatin 100000 unit/gm Cream 15 gm Tube6.5USD tube
Nystatin 100000 unit tablet5.29USD tablet
Nystatin vaginal tablet5.0USD tablet
Pedi-dri topical powder1.82USD g
Nystop 100000 unit/gm powder1.6USD g
Nystatin 500000 unit tablet0.71USD tablet
Nystatin 500000 unit oral tablet0.68USD tablet
Mycostatin 500000 unit orl tablet0.48USD tablet
Nystatin 100000 unit/ml Suspension0.25USD ml
Ratio-Nystatin 500000 unit Tablet0.25USD tablet
Nystatin 100000 unit/gm cream0.1USD g
Pms-Nystatin 100000 unit/ml Suspension0.05USD ml
Ratio-Nystatin 100000 unit/ml Suspension0.05USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Not Available


Experimental Properties
melting point (°C)160 °C (decomposes)MSDS
water solubility360 mg/L (at 24 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP0.5Not Available
Predicted Properties
Water Solubility0.086 mg/mLALOGPS
pKa (Strongest Acidic)3.61Chemaxon
pKa (Strongest Basic)9.11Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count17Chemaxon
Hydrogen Donor Count12Chemaxon
Polar Surface Area319.61 Å2Chemaxon
Rotatable Bond Count3Chemaxon
Refractivity243.55 m3·mol-1Chemaxon
Polarizability100.62 Å3Chemaxon
Number of Rings3Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Human Intestinal Absorption-0.8641
Blood Brain Barrier-0.9581
Caco-2 permeable-0.741
P-glycoprotein substrateSubstrate0.5182
P-glycoprotein inhibitor INon-inhibitor0.814
P-glycoprotein inhibitor IINon-inhibitor0.6721
Renal organic cation transporterNon-inhibitor0.96
CYP450 2C9 substrateNon-substrate0.8313
CYP450 2D6 substrateNon-substrate0.867
CYP450 3A4 substrateNon-substrate0.5273
CYP450 1A2 substrateNon-inhibitor0.916
CYP450 2C9 inhibitorNon-inhibitor0.9374
CYP450 2D6 inhibitorNon-inhibitor0.9354
CYP450 2C19 inhibitorNon-inhibitor0.9243
CYP450 3A4 inhibitorNon-inhibitor0.931
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.987
Ames testNon AMES toxic0.8992
BiodegradationNot ready biodegradable0.8601
Rat acute toxicity2.1245 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9462
hERG inhibition (predictor II)Non-inhibitor0.8971
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)


Mass Spec (NIST)
Not Available
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-052f-0000000295-55c837b332b9a5644b43
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4l-0900000002-fb5e77ff3d1738242582
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0006-0300000495-553d804256891cf2b264
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-08mi-1500000269-f83d3c823fa60aadd462
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0gvk-2700000952-de4881baeaafefcb0ba1
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-03fu-5600002921-a957f99a614b4801bf75
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available


Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Small molecule
Candida albicans
Pharmacological action
  1. Silva L, Coutinho A, Fedorov A, Prieto M: Competitive binding of cholesterol and ergosterol to the polyene antibiotic nystatin. A fluorescence study. Biophys J. 2006 May 15;90(10):3625-31. Epub 2006 Feb 24. [Article]


Pharmacological action
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
Uniprot ID
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
  1. Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, Artursson P: Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem. 2012 May 24;55(10):4740-63. doi: 10.1021/jm300212s. Epub 2012 May 15. [Article]
Pharmacological action
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotre...
Gene Name
Uniprot ID
Uniprot Name
Solute carrier organic anion transporter family member 1B3
Molecular Weight
77402.175 Da
  1. Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, Artursson P: Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem. 2012 May 24;55(10):4740-63. doi: 10.1021/jm300212s. Epub 2012 May 15. [Article]

Drug created at June 13, 2005 13:24 / Updated at July 14, 2024 21:21